Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    GEMCAD 17-01
Previous Study | Return to List | Next Study

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal (BEYOND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03751176
Recruitment Status : Recruiting
First Posted : November 23, 2018
Last Update Posted : February 19, 2020
Sponsor:
Collaborators:
Amgen
Pivotal S.L.
Information provided by (Responsible Party):
Grupo Espanol Multidisciplinario del Cancer Digestivo

Tracking Information
First Submitted Date  ICMJE November 20, 2018
First Posted Date  ICMJE November 23, 2018
Last Update Posted Date February 19, 2020
Actual Study Start Date  ICMJE November 8, 2018
Estimated Primary Completion Date November 30, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 21, 2018)
Progression-free survival at 6 months [ Time Frame: 6 months after inclusion ]
The proportion of subjects progression free at 6 months
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 21, 2018)
  • Progression-free survival (PFS) [ Time Frame: 38 months ]
    Time from randomization to progression or death (Kaplan-Meier estimate)
  • Overall response rate (ORR) [ Time Frame: 38 months ]
    Proportion of subjects with an objective response (complete or partial response) per RECIST 1.1 criteria
  • Overall survival (OS) [ Time Frame: 38 months ]
    Time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cut-off date censored at their last contact date (Kaplan-Meier estimate)
  • Safety and tolerability. ( assessment will consist of monitoring adverse events (AEs), including serious adverse events (SAEs) and laboratory safety parameters) [ Time Frame: 38 months ]
    Safety assessment will consist of monitoring adverse events (AEs), including serious adverse events (SAEs) and laboratory safety parameters. AEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
  • Biomarkers analysis by liquid biopsies. [ Time Frame: 38 months ]
    Conversion rate of RAS/BRAF status according to liquid biopsy determinations at second-line treatment initiation and at the time of disease progression after second-line treatment
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
Official Title  ICMJE Phase II Clinical Trial to Evaluate the Efficacy of Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal Cancer Who Have Received FOLFOX + Panitumumab in First-line
Brief Summary

To estimate progression-free-survival at 6 months in subjects treated in first-line with panitumumab and FOLFOX and with wild type RAS mCRC (metastatic colorectal cancer) confirmed in liquid biopsies before starting second line treatment will be screened for this trial and who have interrupted panitumumab for <3 months (panitumumab continuation). Control arm of subjects treated with FOLFIRI alone will be included.

The combinations of 5-fluorouracil (5-FU) with oxaliplatin (FOLFOX)are considered the backbone chemotherapy for mCRC. Clinical trials have shown the benefit of adding monoclonal antibodies to subjects without mutations in RAS, directed against the epidermal growth factor receptor (EGFR) (cetuximab and panitumumab) to conventional chemotherapy as first-line treatment of mCRC. This trial purposes to study the treatment beyond progression with panitumumab in subjects treated in first-line with an anti-EGFR monoclonal antibody, or rather,the re-introduction of the same targeted therapy after progression to first line.

The clinical hypothesis of this study is that the second-line regimen FOLFIRI + panitumumab, is sufficiently active (defined as a 6-months PFS higher than 30% [based on prior results with second-line FOLFIRI alone] and of at least 50%), justifying further study in this population.

Detailed Description

A phase II, multicentre, open-label, randomized two-arm study. Subjects treated in first-line with panitumumab and FOLFOX and with wild type RAS mCRC confirmed in liquid biopsies before starting second line treatment will be screened for this trial. Only subjects who have interrupted panitumumab for < 3 months (panitumumab continuation) will be included.

Eligible subjects will receive FOLFIRI + panitumumab until disease progression, onset of unacceptable drug toxicities, or subject/physician's request to discontinue. A control arm of subjects treated with FOLFIRI alone will be included. Subjects will be assigned in a 3:2 ratio to receive FOLFIRI + panitumumab (Group A) or FOLFIRI alone (Group B). Randomization will be stratified by primary tumour location (left vs right). A blood sample will be obtained at baseline and at disease progression in order to determine the mutational status of RAS/BRAF and other biomarkers.

Tumour response assessment will be performed by the investigator according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria (version 1.1). Subjects will be evaluated for tumour response every 8 weeks until documentation of disease progression. Responding disease will be confirmed no less than 28 days after the criteria for response are first met. Subjects with symptoms suggestive of progressive disease should be evaluated for tumour progression at the time the symptoms occur. After second-line treatment discontinuation, information on subsequent lines of treatments at the physician discretion and survival will be collected in follow-up visits carried out every 12 weeks (± 4 weeks) until the end of the study (approximately 20 months after the inclusion of the last subject in the study).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Subjects will be assigned in a 3:2 ratio to receive FOLFIRI + panitumumab (Group A) or FOLFIRI alone (Group B). Randomization will be stratified by primary tumour location (left vs right).
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Cancer Metastatic
Intervention  ICMJE
  • Drug: Panitumumab
    Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
    Other Name: Vectibix
  • Drug: Irinotecan
    Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
    Other Name: Any marketed
  • Drug: Folinic acid
    Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
    Other Names:
    • Any marketed
    • Leucovorin
  • Drug: 5-FU
    5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
    Other Names:
    • Any marketed
    • 5-fluorouracil
Study Arms  ICMJE
  • Experimental: FOLFIRI + panitumumab

    Patients received panitumumab plus FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:

    • Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
    • FOLFIRI:
    • Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1
    • Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1
    • 5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
    Interventions:
    • Drug: Panitumumab
    • Drug: Irinotecan
    • Drug: Folinic acid
    • Drug: 5-FU
  • Active Comparator: FOLFIRI

    Patients received FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:

    • Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1
    • Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1
    • 5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
    Interventions:
    • Drug: Irinotecan
    • Drug: Folinic acid
    • Drug: 5-FU
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 21, 2018)
85
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 30, 2022
Estimated Primary Completion Date November 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Man or woman at least 18 years old
  2. Capable of understand, sign and date an informed consent approved by an IEC (investigational Ethics Committee)
  3. Histologically confirmed adenocarcinoma of the colon or rectum in subjects with metastatic disease
  4. Having received a 1st line chemotherapy regimen for mCRC consisting of FOLFOX + panitumumab and having at least achieved stable disease ( i.e., CR (Complete Response) PR (Partial Response) or SD (stable disease) )
  5. Wild-type RAS tumour status confirmed in liquid biopsies before starting second-line treatment
  6. At least one unidimensionally measurable lesion of at least 10 mm per RECIST criteria (version 1.1)
  7. Subjects not candidates for metastasectomy
  8. Tumour disease staging according to RECIST (version 1.1) by investigator up to 4 weeks prior to start of study treatment
  9. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  10. Adequate bone marrow function: neutrophils ≥1.5 x109/ L; platelets ≥100 x109/L; haemoglobin ≥9 g/dL
  11. Hepatic, renal and metabolic function as follows:

    • Total bilirubin count ≤1.5 x upper limit of normal (ULN), ALT (alanine aminotransferase) and AST (aspartate aminotransferase) <2.5 x ULN; or in case of liver metastasis ALT and AST <5 x ULN
    • Renal function, calculated as creatinine clearance or 24-hour creatinine clearance ≥ 50 mL/min
    • Magnesium > lower limit of normal (LLN) -

Exclusion Criteria:

  1. Diagnosis of progressive disease more than 3 months after the last panitumumab administration
  2. First-line PFS of less than 3 months
  3. Subjects given less than 3 months (consecutive) of first-line panitumumab
  4. History of prior or concurrent central nervous system (CNS) metastases
  5. History of another primary cancer, except: curatively treated in situ cervical cancer, or curatively resected non-melanoma skin cancer, or other primary solid tumour curatively treated with no known active disease present and no treatment administered for ≥ 5 years before inclusion
  6. Prior irinotecan therapy
  7. Unresolved toxicities of a previous systemic treatment that, in the opinion of the investigator, cause the subject unfit for inclusion
  8. Prior hormonal therapy, immunotherapy or approved or experimental antibody/proteins ≤ 30 days before inclusion (excluding panitumumab)
  9. Any investigational agent within 30 days prior to inclusion
  10. Evidence of previous acute hypersensitivity reaction, of any grade, to any component of the treatment
  11. History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest computerised tomography
  12. Acute or subacute intestinal occlusion and/or active inflammatory bowel disease or other bowel disease that causes chronic diarrhoea (defined as grade ≥ 2 diarrhoea according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03)
  13. Significant cardiovascular disease including unstable angina or myocardial infarction within 12 months before initiating study treatment or a history of ventricular arrhythmia
  14. History of Gilbert disease or known dihydropyrimidine deficiency syndrome
  15. Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection
  16. Treatment for systemic infection within 14 days before the start of study treatment
  17. History of any disease that may increase the risks associated with study participation or may interfere with the interpretation of study results
  18. Surgery (excluding diagnostic biopsy or placement of a central venous catheter) and/or radiotherapy within 28 days prior to inclusion in the study.
  19. Pregnant or breastfeeding woman
  20. Male or female of childbearing age who do not agree with taking adequate contraceptive precautions, i.e. use contraception double barrier (e.g., diaphragm plus condoms) or abstinence during the course of the study and for 6 months after the last administration of study drug for women and 1 month for men
  21. The subject is unwilling or unable to meet the requirements of the study
  22. Psychological, geographical, familial or sociological conditions that potentially prevent compliance with the study protocol and follow-up schedule. These conditions should be discussed with the subject before inclusion in the trial. -
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Jorge Aparicio, MD +34 606 563 508 japariciou@seom.org
Contact: Anna Triginer +34 93 434 44 12 secretaria@gemcad.org
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03751176
Other Study ID Numbers  ICMJE GEMCAD-17-01
2017-004519-38 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Grupo Espanol Multidisciplinario del Cancer Digestivo
Study Sponsor  ICMJE Grupo Espanol Multidisciplinario del Cancer Digestivo
Collaborators  ICMJE
  • Amgen
  • Pivotal S.L.
Investigators  ICMJE
Study Director: Jorge Aparicio, MD Hospital universitari i Politecnic La Fe
PRS Account Grupo Espanol Multidisciplinario del Cancer Digestivo
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP